<DOC>
	<DOCNO>NCT00072280</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop tumor cell divide stop grow die . Giving combination chemotherapy surgery may shrink tumor remove . Giving combination chemotherapy surgery may kill remain tumor cell . PURPOSE : This phase II trial study well surgery and/or combination chemotherapy work treat child fibrosarcoma .</brief_summary>
	<brief_title>Surgery and/or Chemotherapy Treating Children With Infantile , Congenital , Childhood Fibrosarcoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine event-free relapse-free survival child initially unresectable congenital , infantile , childhood fibrosarcoma treat neoadjuvant chemotherapy comprise vincristine , dactinomycin , cyclophosphamide ( VAC ) definitive local control . Secondary - Determine event-free relapse-free survival patient initially treat regimen follow observation local control positive microscopic margin . - Determine event-free relapse-free survival patient initially treat regimen follow additional chemotherapy comprise etoposide ifosfamide local control gross positive margin . - Determine event-free relapse-free survival patient treat surgery alone . OUTLINE : This pilot , multicenter study . Patients begin treatment accord lesion resectability . Patients resectable lesion proceed surgery . - Surgery : Patients undergo resection disease lesion . Patients clear microscopically positive margin undergo observation . Patients grossly positive margin undergo re-resection feasible . Patients grossly positive margin re-resection re-resection feasible receive chemotherapy comprise vincristine , dactinomycin , cyclophosphamide ( VAC ) . Patients unresectable lesion receive VAC chemotherapy . - VAC chemotherapy : Patients receive vincristine intravenously ( IV ) day 1 , 8 , 15 dactinomycin IV cyclophosphamide IV 1 hour day 1 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients disease progression 2-4 course VAC chemotherapy proceed chemotherapy comprise etoposide ifosfamide ( IE ) . Patients stable disease 4 course VAC chemotherapy proceed IE chemotherapy . Patients partial response ( PR ) unresectable lesion 4 course VAC chemotherapy receive 2 additional course VAC re-evaluated . Patients proceed surgery continue PR achieve complete response ( CR ) lesion resectable . Patients CR PR resectable lesion 4 course VAC chemotherapy proceed surgery . Patients stable disease , progressive disease , PR unresectable lesion 6 course VAC proceed IE chemotherapy . - IE chemotherapy : Patients receive etoposide IV 1 hour ifosfamide IV 1 hour day 1-5 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . Patients CR PR resectable lesion 2-4 course IE chemotherapy proceed surgery . All patient follow every 3 month 6 month , every 6 month 1 year , clinically indicate . PROJECTED ACCRUAL : A total 60-70 patient accrue study within 8 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Fibrosarcoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Dactinomycin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm infantile , congenital , pediatric fibrosarcoma Initial biopsy surgery perform within past 35 day No evidence distant metastasis Available tissue central review PATIENT CHARACTERISTICS : Age Under 2 diagnosis Performance status Zubrod Score ( ECOG ) Life expectancy At least 8 week Hematopoietic Absolute neutrophil count least 1,000/mm^3 Platelet count least 100,000/mm^3* Hemoglobin least 10.0 g/dL* NOTE : *Transfusions allow Hepatic Total bilirubin great 1.5 time upper limit normal ( ULN ) ( patient 4 week age ) Patients 4 week age indirect hyperbilirubinemia eligible , provide follow criterion meet : At least 2 bilirubin value separate timepoints show decrease measurement Direct bilirubin great 20 % total bilirubin Direct bilirubin great 1.5 time ULN Alanine Aminotransferase ( ALT ) less 2.5 time ULN Renal Creatinine clearance radioisotope glomerular filtration rate least 70 mL/min PRIOR/CONCURRENT THERAPY : Biologic therapy No concurrent sargramostim ( GMCSF ) Chemotherapy No prior chemotherapy No concurrent anticancer chemotherapy Endocrine therapy Not specify Radiotherapy No prior concurrent radiotherapy except emergent radiotherapy impend tracheal compression Surgery See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>2 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>childhood fibrosarcoma</keyword>
	<keyword>nonmetastatic childhood soft tissue sarcoma</keyword>
</DOC>